Abstract
This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 200 mg voriconazole twice daily at steady state. When tacrolimus was coadministered with voriconazole, a significant increase in area under its concentration-time curve (AUC0-24) was observed for all genotypes. AUC0-12 of voriconazole in IMs and PMs were significantly higher than that in EMs (P 0-24 of tacrolimus in combination with voriconazole in IMs and PMs were also significantly higher than that in EMs (P
| Original language | English |
|---|---|
| Pages (from-to) | 408-413 |
| Number of pages | 6 |
| Journal | Journal of Clinical Pharmacology |
| Volume | 56 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2016 Apr 1 |
Fingerprint
Keywords
- CYP2C19 polymorphism
- CYP3A
- drug interaction
- tacrolimus
- voriconazole
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
Cite this
Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. / Imamura, Chiyo; Furihata, Kenichi; Okamoto, Shinichiro; Tanigawara, Yusuke.
In: Journal of Clinical Pharmacology, Vol. 56, No. 4, 01.04.2016, p. 408-413.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole
AU - Imamura, Chiyo
AU - Furihata, Kenichi
AU - Okamoto, Shinichiro
AU - Tanigawara, Yusuke
PY - 2016/4/1
Y1 - 2016/4/1
N2 - This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 200 mg voriconazole twice daily at steady state. When tacrolimus was coadministered with voriconazole, a significant increase in area under its concentration-time curve (AUC0-24) was observed for all genotypes. AUC0-12 of voriconazole in IMs and PMs were significantly higher than that in EMs (P 0-24 of tacrolimus in combination with voriconazole in IMs and PMs were also significantly higher than that in EMs (P
AB - This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 200 mg voriconazole twice daily at steady state. When tacrolimus was coadministered with voriconazole, a significant increase in area under its concentration-time curve (AUC0-24) was observed for all genotypes. AUC0-12 of voriconazole in IMs and PMs were significantly higher than that in EMs (P 0-24 of tacrolimus in combination with voriconazole in IMs and PMs were also significantly higher than that in EMs (P
KW - CYP2C19 polymorphism
KW - CYP3A
KW - drug interaction
KW - tacrolimus
KW - voriconazole
UR - http://www.scopus.com/inward/record.url?scp=84960100931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960100931&partnerID=8YFLogxK
U2 - 10.1002/jcph.605
DO - 10.1002/jcph.605
M3 - Article
C2 - 26239045
AN - SCOPUS:84960100931
VL - 56
SP - 408
EP - 413
JO - Journal of Clinical Pharmacology
JF - Journal of Clinical Pharmacology
SN - 0091-2700
IS - 4
ER -